Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00201_DB00640_nanopub.RAXE330bqmyCH4uAC8oxCwCbWLmE5nE3Bk91Put-XWmPc#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00201_DB00640 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00201_DB00640 label "DDI between Caffeine and Adenosine - Caffeine may diminish the therapeutic effect of adenosine. Specific management recommendations vary slightly depending on specific adenosine product used (i.e., therapeutic vs. diagnostic use of adenosine). Significantly higher adenosine doses, or alternative agents, may be required. Monitor for decreased therapeutic effects of adenosine if the patient is already receiving caffeine. Discontinue caffeine in advance (5 half-lives, or approximately 24 hours, is specifically recommended) of scheduled diagnostic use of adenosine (e.g., for radionuclide imaging studies) whenever possible. [drugbank_resource:DB00201_DB00640]" assertion.
- drugbank_resource:DB00201_DB00640 identifier "drugbank_resource:DB00201_DB00640" assertion.
- drugbank_resource:DB00201_DB00640 title "DDI between Caffeine and Adenosine - Caffeine may diminish the therapeutic effect of adenosine. Specific management recommendations vary slightly depending on specific adenosine product used (i.e., therapeutic vs. diagnostic use of adenosine). Significantly higher adenosine doses, or alternative agents, may be required. Monitor for decreased therapeutic effects of adenosine if the patient is already receiving caffeine. Discontinue caffeine in advance (5 half-lives, or approximately 24 hours, is specifically recommended) of scheduled diagnostic use of adenosine (e.g., for radionuclide imaging studies) whenever possible." assertion.
- drugbank:DB00640 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00201_DB00640 assertion.
- drugbank:DB00201 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00201_DB00640 assertion.